SCHEMBL660844

SCHEMBL660844

CC1(C)C(=O)CCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1549719 0.86 CRBN (0.40)
SCHEMBL11862409 0.83 CRBN (0.38)
SCHEMBL11864393 0.83 CRBN (0.38)
SCHEMBL11861618 0.83 CRBN (0.38)
SCHEMBL11867517 0.83 CRBN (0.38)
SCHEMBL15659511 0.77 CRBN (0.33)
SCHEMBL255341 0.77
SCHEMBL10588951 0.72 MAPT (0.42)
SCHEMBL12493703 0.72
SCHEMBL15656868 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114773279-B Novel synthesis method of metconazole 浙江工业大学 2023-12-05 CN claimed
CN-114773279-A Novel synthesis method of metconazole 浙江工业大学 2022-07-22 CN claimed
CN-118084640-A Preparation method of metconazole key intermediate 5- (4-chlorophenyl) methyl-2, 2-dimethylcyclopentanone 临海市建新化工有限公司 2024-05-28 CN disclosed
US-20240148732-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS SCHRÖDINGER, INC. 2024-05-09 US disclosed
EP-4284804-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS Schrödinger, Inc. (US) 2023-12-06 EP disclosed
CN-114773279-B Novel synthesis method of metconazole 浙江工业大学 2023-12-05 CN disclosed
CN-114773279-B Novel synthesis method of metconazole 浙江工业大学 2023-12-05 CN disclosed
CN-117120442-A Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders 薛定谔公司 2023-11-24 CN disclosed
CN-116969545-A Method for removing odor substances in water body by utilizing low-temperature plasma generated by dielectric barrier discharge 哈尔滨工业大学 2023-10-31 CN disclosed
WO-2022164789-A9 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS SCHRÖDINGER, INC. (US) 2023-05-25 WO disclosed
WO-2022164789-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS SCHRÖDINGER, INC. (US) 2022-08-04 WO disclosed
WO-2006101867-A2 TREATMENT OF INFLAMMATORY BOWEL DISEASE ALLERGAN, INC. (US) 2006-09-28 WO disclosed
EP-1608309-A2 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE Allergan, Inc. (US) 2005-12-28 EP disclosed
US-20050164992-A1 Treating inflammatory bowel disease by administering prostaglandin derivatives such as (3-{(1R,4S,5S)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid methyl ester ALLERGAN, INC. (US) 2005-07-28 US disclosed
US-6875787-B2 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure ALLERGAN, INC. (US) 2005-04-05 US disclosed
EP-1487789-A2 IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS Charterhouse Therapeutics Ltd. (GB) 2004-12-22 EP disclosed
US-20040235958-A1 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure ALLERGAN, INC. 2004-11-25 US disclosed
WO-2004071428-A2 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN, INC. (US) 2004-08-26 WO disclosed
US-20040157901-A1 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN, INC. 2004-08-12 US disclosed
WO-2003082813-A2 IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS CHARTERHOUSE THERAPEUTICS LIMITED (GB) 2003-10-09 WO disclosed